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Abstract
Objective: To assess the potential benefit of treating patients with 
acute ischemic stroke using intra-arterial methods. 
Methods: A meta-analysis of published randomized controlled trials 
that compared standard therapy with intravenous tissue plasmino-
gen activator (IVtPA) for thrombolysis to intra-arterial therapies in 
patients with acute stroke was performed. All studies reported were 
analyzed as one group and studies documenting patients with large 
vessel obstruction were analyzed as a second group. The standardi-
zed mean difference (SMD) and the odds ratio (OR) of the dichoto-
mized outcomes of Modified Rankin Scale (mRS) of these trials was 
calculated. 
Results: Nine trials were identified with 2,711 patients treated. Me-
ta-analysis of all studies, with and without large vessel obstruction 
documented, showed a significant benefit with intra-arterial therapy 
(SMD: 0.22 +/- 0.041; P=0.003). The dichotomized outcomes of mRS 
of these trials showed significant improvement (OR: 1.66 - 2.43 in 
four of the five treatment arm groups examined). Meta-analysis of 
all publications with large vessel obstruction documented as an entry 
criteria showed a greater significant benefit with intra-arterial therapy 
(SMD: 0.35 +/- 0.05; P<0.001). The dichotomized outcomes of mRS of 
these trials showed significant improvement (OR: 1.36 - 2.38 in all five 
treatment arm groups examined). Some heterogeneity was observed 
between studies.
Conclusion: Treatment of patients with acute ischemic stroke was 
associated with improved outcomes as measured by mRS. Patient se-
lection, standard treatment, and study treatment factors contributed 
to the statistical evaluation of inter study heterogeneity and may have 
contributed to different study outcomes. 
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Introduction
Stroke is a major cause of disability, with more than 
795,000 individuals affected and about 130,000 
deaths in the United States each year. About 87% 
of strokes are caused by vascular obstruction. [1] A 
number of medical advances over the last twen-
ty years have positively impacted patient outcome 
in patients with acute ischemic stroke. The use of 
intravenous tissue plasminogen activator (IV tPA) 
for thrombolysis was first approved by the FDA in 
1996. [2] It was estimated that 1% to 6% of ische-
mic stroke patients were treated with IV tPA in the 
early years following its approval. This low number 
was largely due to the strict 3-hour time window 
recommended for treatment and fears about com-
plications related to its use. [3, 4] The use of IV tPA 
became more widely accepted after 2008 when a 
randomized controlled trial reported significantly 
improved clinical outcomes in patients treated less 
than 4.5 hours after symptom onset. [5, 6] 
New treatments are being developed for patients 
with acute stroke, including the use of mechani-
cal devices to remove arterial obstructions. Endo-
vascular mechanical devices for thrombus removal 
became widely available in about 2005. [7] These 
devices have significantly improved in efficacy and 
safety over time, as demonstrated by randomized 
controlled trials. [8, 9] The benefit of intra-arterial 
thrombus treatment using mechanical devices is 
still under investigation.  The use of intra-arterial 
thrombolysis with enzymatic materials is also under 
active investigation and may result in similar outco-
mes as those found with thrombus removal devi-
ces. [10] Outcomes of studies of these treatments in 
patients with acute ischemic stroke have not been 
consistent. We performed a meta-analysis to bet-
ter understand the potential benefit associated with 
the intra-arterial treatment of patients with acute 
ischemic stroke and risk factors for good or poor 
outcomes after treatment.
Outcomes of studies of these treatments in pa-
tients with acute ischemic stroke have not been 
consistent.  We performed a meta-analysis to bet-
ter understand the potential benefit associated with 
the intra-arterial treatment of patients with acute 
ischemic stroke and risk factors for good or poor 
outcomes after treatment.
Methods
A meta-analysis was performed of published peer-
reviewed randomized controlled trials comparing 
standard therapy to intra-arterial therapeutic pro-
cedures for the treatment of patients with acu-
te thrombotic stroke per PRISMA standards (see 
Supplemental File I for PRISMA Checklist). Standard 
of care was defined as the use of IV tPA in the 
control arm. [5] Trials not using IV tPA in the control 
arm were excluded. [11-15] Non-randomized pros-
pective studies, studies with historical controls, and 
retrospective series were excluded from the analysis.
A search of PubMed, the Cochrane Central Regis-
ter of Controlled trials, Science Direct, and Clinical-
Trials.gov was performed for randomized controlled 
trials using the terms “stroke" AND “thrombec-
tomy” (MeSH unique IDs D020521 and D017131, 
respectively). Abstracts for all articles published 
before March, 2016 were reviewed. Bibliographies 
of relevant articles were reviewed to identify any 
additional relevant articles. Articles, databases, and 
supplemental appendices were searched for sup-
porting data. Data were extracted in an unblinded 
fashion and rechecked on three separate occasions. 
No abstracts or unpublished studies were included 
in the study. Modified Rankin Scale (mRS) at 90 days 
was used to measure neurologic outcomes in the 
identified studies. [16] 
Statistical Analysis
Data were analyzed for all patients and also sepa-
rately for patients in studies that screened for lar-
ge vessel obstruction as entry criteria. StatsDirect 
(Version 3) was used to perform meta-analysis of 
standardized mean difference (SMD) of mRS and 
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odds ratio (OR) of outcome of different dichoto-
mous outcomes of mRS. Both fixed effects model 
and random effects model were used to examine 
the overall effect of treatments. Hedges g statistic 
was used to assess the SMD in the fixed effects 
model. The Mantel-Haenszel method was used for 
calculating the weighted summary OR in the fixed 
effects model. Cochran’s Q test and I2 statistic were 
used to estimate study heterogeneity. The Chi squa-
re statistic was used to evaluate different sources of 
study heterogeneity in groups with non-zero outco-
mes. The Cochrane risk of bias tool was used to as-
sess publication bias. [17] Additional study methods 
including risk of bias and study heterogeneity are 
elaborated in Supplemental File II.
Risk factors for variations in study outcome inclu-
ded the use of first generation devices for endovas-
cular treatments, general anesthesia, intra-arterial 
tPA in the treatment arms, and variable use of IV 
tPA in the control and treatment arms of each stu-
dy. Time to treatment with clot removal therapies 
is critical to patient outcome. Heterogeneity in re-
ported data made evaluation of time from onset of 
stroke event to each treatment modality difficult to 
evaluate and this analysis was not performed.
Results
A total of 946 publications were identified from the 
literature search, from which 102 were identified for 
detailed review (Figure 1). Eleven clinical trials met 
the search criteria. [18-29] Among these, a single 
trial of seven patients not presenting mRS outcome 
data was excluded. [18] Another trial that included 
Figure 1:  Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) four-phase flow 
diagram of included and excluded studies for quantitative analysis.
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an intravascular therapeutic procedure in both arms 
was also excluded. [19] Nine trials were suitable for 
meta-analysis (Table 1). [20-29] Of these trials, seven 
accepted patients after initial screening identified 
large vessel obstruction. [22, 24-29] These studies 
were also evaluated in a separate meta-analysis. 
Additional study results including risk of bias and 
study heterogeneity are elaborated in Supplemental 
File II. 
All publications, with and without large 
vessel obstruction documented
Nine randomized controlled trials were identified 
that compared the use of IV tPA to that of intra-
arterial treatment in patients with acute ischemic 
stroke (Table 1). [20-23, 25-29] Not all trials had 
documentation of large vessel obstruction as an 
entry criteria. [20, 21, 23] Patients in the SYNTHE-
SIS PILOT AND SYNTHESIS studies had a higher 
frequency of male gender than the other studies 
(Chi square test, P=0.000527) (Supplemental File 
III). Patient age and race was not evaluable bet-
ween studies. 
The mean mRS of the control and treatment 
groups was evaluated. The SMD of the treatment 
group mRS was decreased compared to the con-
trol group in the fixed effects model 0.22 +/- 0.041 
and the random effects model 0.25 +/- 0.085. The 
standardized mean difference of the two groups 
was significantly different (Funnel plot, Figure 2A, 
Fixed effects model, P<0.001; Random effects 
model, P=0.003). Significant study heterogeneity 
was observed (Cochran’s Q test for heterogenei-
ty, P=0.0003, I2 statistic for inconsistency, 72.5%). 
Significant heterogeneity was observed with inclu-
Table 1. Studies evaluated.
Study Obstruction† Treatment  Treated Treatment  Treated
Synthesis pilot IV tPA 29 IA tPA with mechanical thrombectomy if needed 25
Synthesis IV tPA 181 IA tPA with mechanical thrombectomy if needed 181
IMS III IV tPA 214 IV tPA plus IA tPA, mechanical thrombectomy, or both 415
MR rescue X IV tPA 54 IV tPA plus mechanical thrombectomy with rescue IA tPA 64
IMS III X IV tPA 91 IV tPA plus IA tPA, mechanical thrombectomy, or both 180
MR clean X IV tPA 267 IV tPA plus IA tPA, mechanical thrombectomy, or both 233
Escape X IV tPA 146 IV tPA plus mechanical thrombectomy 164
Extend-IA X IV tPA 35 IV tPA plus mechanical thrombectomy 35
Revascat X IV tPA 103 IV tPA plus mechanical thrombectomy 103
Swift prime X IV tPA 93 IV tPA plus mechanical thrombectomy 98
† X: All patients screened for large vessel proximal arterial obstruction. IV tPA: Intravenous tissue plasminogen activator. 
IA tPA: Intra-arterial tissue plasminogen activator
Figure 2:  The size of the square marker is re-
lative to study weight. The location of 
the diamond represents the estimated 
effect size and the width the precision 
of the estimate.
A) Standardized mean difference of control and treatment group mRS, including all 
patient studies. A significant reduction in mRS was associated with intravascular 
treatment. B) Standardized mean difference of control and treatment group mRS, 
including all patient studies and removal of studies associated with heterogeneity. A 
significant reduction in mRS was associated with intravascular treatment. 
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sion of the Synthesis, [21] MR Rescue, [22] and 
IMS III [23] trials in the meta-analysis (Funnel plots, 
Figures 2A and 2B). Excluding these trials, the SMD 
of the treatment group was decreased compared 
to the control group in the fixed effects model 
0.38 +/- 0.055 and the random effects model 0.39 
+/- 0.067. The standardized mean difference of 
the two groups was significantly different (Figure 
2B, Fixed effects model, P<0.001; Random effects 
model, P<0.001). Minimal heterogeneity was ob-
served after exclusion of these trials (Cochran’s Q 
test for heterogeneity, P=0.26, I2 statistic for in-
consistency, 23.7%). 
The OR of different dichotomized outcomes of 
the mRS was evaluated (Table 2). Increments in mRS 
of the positive dichotomous outcome were asso-
ciated with a monotone increase in the number of 
patients in that group. Significant heterogeneity 
was observed with inclusion of the Synthesis, [21] 
MR Rescue, [22] and IMS III [23] trials in the meta-
analysis. Excluding these trials, meta-analysis of the 
remaining six trials showed minimal heterogeneity. 
The meta-analysis of the OR of the dichotomized 
outcomes of these six trials showed significant 
association with improvement in four of the five 
treatment arm groups examined. The OR benefit 
ranged from 1.66 to 2.43, with the largest benefit 
seen in the best outcome mRS subgroup. 
Series with large vessel obstruction as 
entry criteria
Nine randomized controlled trials were identified 
that compared the use of IV tPA to that of intra-
arterial treatment in patients with acute ischemic 
Table 2.  Odds ratio meta-analysis and study heterogeneity. All patients (excluding SYNTHESIS, MR RES-
CUE, and IMS III trials) and studies with large vessel obstruction as entry criteria (excluding MR 
RESCUE trial).
mRS 
outcomes
All Patients Patients with Visualized Obstruction
Odds 
ratio
95% CI P
Study Heterogeneity
Odds 
ratio
95% CI P
Study Heterogeneity
Cochran's 
Q, 
P value
I2 
Statistic 
(%)
Cochran's 
Q,
P value
I2 
Statistic 
(%)
0-1 vs 2-6
Fixed effects 
model
2.43 1.83-3.24 <0.001
0.93 0.0
2.38 1.82-3.10 <0.001
0.92 0.0
Random effects 
model
2.43 1.82-3.24 <0.001 2.38 1.82-3.10 <0.001
0-2 vs 3-6
Fixed effects 
model
2.4 1.90-3.03 <0.001
0.75 0.0
2.17 1.75-2.70 <0.001
0.34 11.9
Random effects 
model
2.4 1.90-3.03 <0.001 2.17 1.73-2.76 <0.001
0-3 vs 4-6
Fixed effects 
model
2.23 1.78-2.78 <0.001
0.24 25.4
2.12 1.73-2.61 <0.001
0.17 37.4
Random effects 
model
2.26 1.71-2.99 <0.001 2.17 1.64-2.86 <0.001
0-4 vs 5-6
Fixed effects 
model
1.66 1.30-2.13 <0.001
0.16 36.9
1.74 1.38-2.19 <0.001
0.29 18.3
Random effects 
model
1.71 1.21-2.42 0.003 1.77 1.36-2.31 <0.001
0-5 vs 6
Fixed effects 
model
1.22 0.92-1.63 0.17
0.29 18.5
1.36 1.05-1.78 0.022
0.23 27.1
Random effects 
model
1.24 0.88-1.74 0.23 1.41 1.01-1.96 0.044
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stroke. [20-29] Two trials did not document large 
vessel obstruction as an entry criteria [20, 21] and 
were excluded from this analysis. One trial, IMS III, 
[23] was modified late in its accrual history to have 
absence of large vessel obstruction as an exclusion 
criteria. [24] Outcomes of patients with large vessel 
obstruction from this study were reported separa-
tely and were available for analysis. [24] Seven of 
the identified randomized controlled trials that in-
cluded large vessel obstruction as an entry criteria 
were used for this meta-analysis (Table 1). [22, 24-
29] Patient demographics were similar for the two 
treatment arms (Supplemental File III).
The mean mRS of the control and treatment 
groups was evaluated. The SMD of the treatment 
group mRS was decreased compared to the control 
group 0.35 +/- 0.05 in the fixed effects model and 
0.35 +/- 0.074 in the random effects model. The 
standardized mean difference of the two groups 
was significantly different (Funnel plot, Figure 3A, 
Fixed effects model, P<0.001, Random effects mo-
del, P< 0.001). Significant heterogeneity was obser-
ved with inclusion of the MR Rescue [22] trial in the 
meta-analysis (Cochran’s Q test for heterogeneity, 
P= 0.0615, I2 statistic for inconsistency, 50.1%; Fun-
nel plots, Figures 3A and 3B). Excluding this trial, the 
SMD of the treatment group was decreased compa-
red to the control group, 0.38 +/- 0.052 in the fixed 
effects model and 0.39 +/- 0.060 in the random 
effects model. The standardized mean difference 
of the two groups was significantly different (Figure 
3B) (Fixed effects model, P<0.001; Random effects 
model, P<0.001). Minimal heterogeneity was obser-
ved after exclusion of this trial (Cochran’s Q test for 
heterogeneity, P= 0.27, I2 statistic for inconsistency, 
22.0%). 
The OR of different dichotomized outcomes of 
the mRS was evaluated (Table 2). Increments in mRS 
of the positive dichotomous outcome was associa-
ted with a monotone increase in the number of pa-
tients in that group. Significant heterogeneity was 
observed with inclusion of the MR Rescue [22] trial 
in the meta-analysis. Meta-analysis of the six remai-
ning trials, the same trials as those examined for the 
SMD mRS analysis, showed minimal heterogeneity. 
The meta-analysis of the OR of the dichotomized 
outcomes of these six trials showed significant asso-
ciation with improvement in all five treatment arm 
groups examined. The OR benefit ranged from 1.36 
to 2.38, with the largest benefit seen in the best 
outcome mRS subgroup.
Risk of Bias
The risk of bias tool indicated a low risk of publi-
cation bias in the evaluated studies (Supplemental 
File I). All studies used a random component in the 
sequence generation process and a recommended 
procedure to conceal allocation prior to assignment. 
While patients and providers were not blinded to 
their treatment, the mRS outcome was not likely 
to be influenced by the lack of blinding. All studies 
used an assessor of mRS outcome that was blinded 
to treatment arm. Six of the studies had no missing 
outcome data and the remaining 4 studies had 0 to 
3.7% missing mRS values in the intra-arterial arm 
and 2 to 5.1% missing in the IV tPA arm. These 
Figure 3:  The size of the square marker is relative 
to study weight. The location of the dia-
mond represents the estimated effect 
size and the width the precision of the 
estimate.
A) Standardized mean difference of control and treatment group mRS, including 
studies using large vessel obstruction as inclusion criteria. A significant reduction in 
mRS was associated with intravascular treatment. B) Standardized mean difference 
of control and treatment group mRS, including studies using large vessel obstruction 
as inclusion criteria, and removal of one study associated with heterogeneity. A 
significant reduction in mRS was associated with intravascular treatment. 
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missing outcome data are unlikely to be related 
to true outcome. This missing data was balanced 
across treatment groups and the reasons for their 
absence were similar. No missing data was imputed. 
Nine of the 10 treatment protocols were available 
for review. Six studies had all planned outcomes 
reported, two were only missing financial outco-
mes, and two were missing redundant secondary 
outcomes. Other bias included patients randomized, 
but not receiving treatment, usually due to lack of 
obstruction found during imaging studies, marked 
clinical improvement or deterioration, or technical 
problems. All these patients were included in the 
mRS analyses.
Discussion
The study of intra-arterial treatment of acute ische-
mic stroke has mixed outcomes. While IV tPA has 
been significantly associated with improved outco-
mes, [5] intra-arterial thrombolytic treatments have 
not been uniformly successful. This meta-analysis of 
nine studies showed superior outcome in patients 
treated with intra-arterial thrombus-removing the-
rapy, compared to patients treated with standard IV 
tPA therapy alone. This finding was observed in four 
of five dichotomous mRS subgroups derived from 
all patients treated in this fashion (Table 2). The 
finding of superior outcome was stronger in studies 
where large vessel obstruction was a criterion for 
protocol entry. All five dichotomous mRS subgroups 
derived from studies with large vessel obstruction 
as a criterion for protocol entry had better outco-
mes than the control groups (Table 2). The random 
effects model showed minimal benefit over the fi-
xed effects model, suggesting there was one true 
benefit in all the studies evaluated. 
The mixed results found in treated patients could 
be attributed to variations in protocol entry criteria 
and patient management, and changes in treatment 
modalities over time. [30] We examined how these 
factors contributed to inter-study heterogeneity that 
could result in different treatment outcomes and 
their relationship with reported outcomes.
Early trials often did not include large vessel 
obstruction as entry criteria. This likely resulted 
in unnecessary intra-arterial treatments, possible 
with the under general anesthesia, administered 
to stroke patients without large vessel obstruction. 
Early administration of IV tPA, before the adminis-
tration of intra-arterial treatment, has the potential 
to clear an occluding arterial thrombus, making de-
tection of benefit from intra-arterial therapy more 
difficult. From 2.9 to 3.4% of patients randomized 
to intra-arterial treatment in studies evaluated here 
had marked clinical improvement after the start of 
IV tPA that led to not receiving their intra-arterial 
treatment. [21, 25, 27] Receiving intra-arterial the-
rapy after IV tPA can be an unnecessary treatment 
associated with serious complications including in-
tracranial hemorrhage, arterial perforation, air em-
boli, and adverse reactions to general anesthesia. 
[10, 31] Inclusion of patients like these could have 
confounded the benefit analyses of intra-arterial 
therapies. From 3.4 to 18.4% of study patients 
evaluated here did not have large vessel obstruc-
tion at the time of intra-arterial treatment imaging 
[22-27, 32] and the frequency of obstruction in 
patients not having obstruction evaluated is not 
known. Patients in the SYNTHESIS PILOT, SYNTHE-
SIS, and early IMS III trials were accepted on the 
basis of clinical findings of acute stroke, without 
any demonstration of thrombus obstruction. [21] 
There was no clear benefit associated with the use 
of intra-arterial treatment in these trials. Based on 
our analysis, the patients most likely to benefit 
from intra-arterial therapy would have a thrombus 
occluding a large artery after IV tPA treatment. 
The most commonly obstructed large arteries were 
the internal carotid artery and M1 and M2 middle 
cerebral arteries. Treatment of obstruction in these 
arteries appears to be associated with the best res-
ponses. Further study is needed to better evaluate 
outcomes in patients with extra-cranial internal ca-
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rotid artery, M3 middle cerebral artery, and basilar 
artery obstruction.
Differences in patient management also contri-
buted to study heterogeneity. While all patients 
in studies’ control arm were scheduled for IV tPA 
by protocol, not all patients received treatment. In 
addition, some studies did not include IV tPA as 
part of the treatment arm, and when IV tPA was 
included, not all patients received this treatment. 
These unpredictable variations in the numbers of 
patients receiving IV tPA likely affect study outcome. 
IV tPA was not used in patients receiving endovas-
cular treatment in the Synthesis Pilot and Synthesis 
trials, and used inconsistently in treated patients in 
MR RESCUE. No clear benefit was observed with 
the use of intra-arterial treatment in these trials. The 
effect of initial treatment with IV tPA on subsequent 
inra-arterial treatment needs further study.
Approximately 6.8 to 38.8% of patients un-
dergoing endovascular treatments receive general 
anesthesia. This variation suggests a range in tech-
nical expertise of the physicians performing these 
special procedural treatments. General anesthesia 
has been reported as a risk factor for poor outcome 
in patients affected by stroke. [33, 34] However, 
patients we evaluated in the studies with frequently 
reported use of general anesthesia during adminis-
tration of intra-arterial treatment did as well as pa-
tients in the studies with infrequent use. The reason 
for the good outcome observed in these studies 
with more frequent use of general anesthesia is not 
clear. Further study is needed to understand the 
safety of general anesthesia use in patients with 
acute ischemic stroke.
Improvements in mechanical devices to remove 
thrombi have been reported. The Merci Retriever, a 
first generation device, used corkscrew-shaped coil 
loops of flexible nitinol wire to ensnare and remove 
thrombus. Second generation thrombectomy devi-
ces used a different design resembling intracranial 
stents. The use of second generation devices has 
been shown to result in significant benefit over 
the Merci Retriever, as measured by recanalization 
studies and long term functional outcome. [8, 9] 
The use of the Merci Retriever was associated with 
higher risk of arterial perforation, [8] worse neuro-
logic outcome, [8, 9] and higher mortality [9] than 
other stents. First generation devices were most 
frequently used as the sole intra-arterial treatment 
in MR RESCUE and IMS III, studies not associated 
with improved outcome after intra-arterial therapy.
Intra-arterial administration of thrombolytic 
agents for the treatment of acute stroke is not as 
well studied as intravenous treatment. Intra-arterial 
administration of thrombolytic agents appears to 
be associated with a modest benefit, although their 
evaluation is on-going. [10, 35] Some studies have 
shown a higher rate of arterial recanalization com-
pared to intravenous treatments, spurring interest in 
this treatment modality. [35] The use of intra-arterial 
thrombolytic agents appears to be associated with 
more frequent occurrences of intracranial hemorr-
hage. [10] In IMS III, Synthesis Pilot, and Synthesis, 
intra-arterial tPA was most frequently used to re-
move obstructing clot. These studies were not as-
sociated with improved outcome after intra-arterial 
therapy.
Patients with larger ischemic cores are at higher 
risk for poor outcome after removal of proximal 
large arterial occlusions. [30, 36, 37] Patients with 
small infarct volumes have been reported to do bet-
ter than those with larger infarct volumes. [38] Early 
studies did not use ischemic core size cutoff to se-
lect patients and were associated with worse outco-
me. Studies treating patients with a relatively small 
ischemic core volume, Extend-IA, MR Clean, Esca-
pe, Revascat, and Swift Prime, were associated with 
improved outcomes after intra-arterial treatment. 
This study was limited by data not adequately 
reported or unavailable for retrospective analyses 
and differences in methodologies used in patient 
selection and treatment. This made the statistical 
evaluation of heterogeneity limited in nature. Cli-
nical heterogeneity, including variations in physi-
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cian patterns of treatment, patient selection and 
patient variability, could not be compared between 
studies. The use of different mechanical devices for 
thrombus removal, varying times to standard and 
intra-arterial treatments after onset of stroke, and 
pooling of different interventions in the treatment 
arm also contributed to inter-study heterogeneity 
and could not be accounted for. 
The best outcomes were seen in a small sub-
group of patients who developed stroke. These 
patients were treated with newer generation me-
chanical thrombectomy devices, had evidence of 
large vessel obstruction on initial imaging studies, 
had obstruction of the internal carotid artery and 
M1 and M2 middle cerebral arteries, had small core 
stroke volumes, and had the most consistent and 
apparently rapid use of IV tPA (less than 4.5 hours) 
and mechanical thrombectomy devices (less than 
6 to 8 hours) to remove thrombus. Treatment of 
patients without apparent obstruction, cerebral he-
morrhage, more distal large artery obstruction or 
small artery obstruction, larger ischemic stroke core 
size, and who present in a delayed fashion is still 
controversial. Further studies are needed to better 
delineate patient outcomes in these varied clinical 
scenarios.
Conclusion
This meta-analysis demonstrated improved outco-
mes as measured by mRS in patients with acu-
te thrombotic stroke undergoing intra-arterial 
treatment. This improvement appears to be com-
plementary to the improvement seen with IV tPA. 
Patient selection, standard treatment, and study 
treatment factors contributed to inter study hete-
rogeneity, which may have resulted in different stu-
dy outcomes in the different reports. These factors 
need further study to determine best outcome in 
different patient populations. 
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